According to reports in the New England Journal of Medicine, US researchers treated a 52-year-old man of melanoma by cloning cells from the patients own defence system and injecting them back into his body, in a process known as "immunotherapy".
The man was free from tumours within eight weeks of undergoing the procedure. After two years he is still free from the disease which had spread to his lymph nodes and one of his lungs. "For this patient we were successful, but we would need to confirm the effectiveness of therapy in a larger study," Dr Cassian Yee, who led the team at the Fred Hutchinson Cancer Research Centre in Seattle.
The treatment, which is extremely expensive at this stage of development, showed that vast numbers of immune cells in the body can be safely and effectively used to treat skin cancer, The Daily Telegraph of Britain said today.
It raises hopes that this approach could not only offer a more effective treatment for skin cancer, or melanoma, but be applied to other cancers too. Larger, more elaborate, trials are now under way, the report said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
